304 related articles for article (PubMed ID: 31984532)
21. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
[TBL] [Abstract][Full Text] [Related]
22. Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies.
Wang L; Yao H; Tong T; Lau K; Leung SY; Ho JWK; Leung WK
Helicobacter; 2022 Apr; 27(2):e12871. PubMed ID: 34969161
[TBL] [Abstract][Full Text] [Related]
23. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
24. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
[TBL] [Abstract][Full Text] [Related]
26. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y
Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
[TBL] [Abstract][Full Text] [Related]
27. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
28. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
29. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Zhang M; Chen CY; Wang XT; Lyu B
Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
[No Abstract] [Full Text] [Related]
30. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
[TBL] [Abstract][Full Text] [Related]
31. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
32. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
[TBL] [Abstract][Full Text] [Related]
33. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes.
Yang YJ; Wu CT; Ou HY; Lin CH; Cheng HC; Chang WL; Chen WY; Yang HB; Lu CC; Sheu BS
Ann Med; 2017 Sep; 49(6):479-486. PubMed ID: 28266875
[TBL] [Abstract][Full Text] [Related]
34. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
[TBL] [Abstract][Full Text] [Related]
35. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota.
Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Chen YH; Tsai TJ; Wu DC; Tsai KW
J Gastroenterol Hepatol; 2019 Nov; 34(11):1968-1976. PubMed ID: 31115933
[TBL] [Abstract][Full Text] [Related]
36. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
Liao XM; Nong GH; Chen MZ; Huang XP; Cong YY; Huang YY; Wu BH; Wei JQ
World J Gastroenterol; 2015 May; 21(20):6310-6. PubMed ID: 26034367
[TBL] [Abstract][Full Text] [Related]
37. Eradication rates in Italian subjects heterogeneously managed for Helicobacter pylori infection. Time to abandon empiric treatments in Southern Europe.
Di Ciaula A; Scaccianoce G; Venerito M; Zullo A; Bonfrate L; Rokkas T; Portincasa P
J Gastrointestin Liver Dis; 2017 Jun; 26(2):129-137. PubMed ID: 28617882
[TBL] [Abstract][Full Text] [Related]
38. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis.
Kuo YT; Liou JM; El-Omar EM; Wu JY; Leow AHR; Goh KL; Das R; Lu H; Lin JT; Tu YK; Yamaoka Y; Wu MS;
Lancet Gastroenterol Hepatol; 2017 Oct; 2(10):707-715. PubMed ID: 28781119
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Helicobacter pylori infection: a review of the world literature.
van der Hulst RW; Keller JJ; Rauws EA; Tytgat GN
Helicobacter; 1996 Mar; 1(1):6-19. PubMed ID: 9398908
[TBL] [Abstract][Full Text] [Related]
40. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
Aktaş B; Başyiğit S; Yüksel O; Akkan T; Atbaşı ST; Uzman M; Yılmaz B; Şimşek G; Nazlıgül Y
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):769-75. PubMed ID: 25919773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
